All In Biotech

Drug Trial Radar · NCT07080034

Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis

A Randomized Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

198

Planned (sponsor's estimate)

Start

Aug 14, 2025

Primary completion

Jan 2027

Study completion Oct 2028

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Jul 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of study drug (BCD-261) in comparison with placebo and to characterize the dose-response relationship in patients with moderate to severe active ulcerative colitis. The study will be conducted in a population of male and female subjects ≥18 years and ≤75 years with moderate to severe active ulcerative colitis and an inadequate response to prior treatment with glucocorticoids, immunosuppressants, or biologics/targeted immunosuppressants.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • anti-TL1A monoclonal antibody, low doseBiological

    injection

  • anti-TL1A monoclonal antibody, medium doseBiological

    injection

  • anti-TL1A monoclonal antibody, high doseBiological

    injection

  • PlaceboOther

    injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who achieved clinical remissionTime frame: week 14

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • "South Ural State Medical University" of the Ministry of Health of the Russian Federation

    Chelyabinsk, Russia · Recruiting

  • Federal Siberian Scientific and Clinical Center of the Federal Medical and Biological Agency

    Krasnoyarsk, Russia · Recruiting

  • Regional State Healthcare Institution "Regional Clinical Hospital"

    Krasnoyarsk, Russia · Recruiting

  • Llc "Olla-Med"

    Moscow, Russia · Recruiting

  • Moscow Clinical Scientific and Practical Center named after A.S. Loginov of the Moscow City Health Department

    Moscow, Russia · Recruiting

  • State Healthcare Institution of the City of Moscow "V.M. Buyanov City Clinical Hospital of the Moscow City Healthcare Department"

    Moscow, Russia · Recruiting

  • Branch of the LLC "Hadassah Medical LTD"

    Moscow, Russia · Recruiting

  • State Institution of Healthcare of the Moscow Region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"

    Moscow, Russia · Recruiting

  • Llc "Novosibirsk Gastrocenter"

    Novosibirsk, Russia · Recruiting

  • Federal State Educational Institution of Higher Education "North-West State Medical University named after I.I. Mechnikov" of the Ministry of Health of the Russian Federation

    Saint Petersburg, Russia · Recruiting

  • Saint Petersburg State Healthcare Institution "City Hospital of the Holy Martyr Elizabeth"

    Saint Petersburg, Russia · Recruiting

  • Federal State Educational Institution of Higher Education "First Saint Petersburg State Medical University named after Academician I.P. Pavlov" of the Ministry of Health of the Russian Federation

    Saint Petersburg, Russia · Recruiting

  • LLC "Research Center Eco-Safety"

    Saint Petersburg, Russia · Recruiting

  • State Healthcare Institution Ulyanovsk Regional Clinical Hospital

    Ulyanovsk, Russia · Recruiting

  • State Healthcare Institution "Primorsky Regional Clinical Hospital No. 1"

    Vladivostok, Russia · Recruiting

  • LLC Medical Center "ASTRA"

    Barnaul, Altayskiy Kray, Russia · Recruiting

  • Republican Clinical Hospital named after G.G. Kuvatov

    Ufa, Bashkortostan Republic, Russia · Recruiting

  • Federal State Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation

    Rostov-on-Don, Rostov Oblast, Russia · Recruiting

  • Federal State Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation

    Rostov-on-Don, Rostov Oblast, Russia · Recruiting

  • State Autonomous Institution of Healthcare "Republican Clinical Hospital of the Ministry of Healthcare of the Republic of Tatarstan"

    Kazan', Tatarstan Republic, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.